NLRP3 and COVID-19: Furthermore, several phase II clinical trials are testing direct NLRP3 inhibition in patients with either mild or severe COVID-19, such as NCT04382053 by Novartis (https://clinicaltrials.gov/ct2/history/NCT04382053?V_34=View#StudyPageTop) and NCT04540120 by Olatec Therapeutics (https://www.sciencedirect.com/science/article/pii/B9780323918022000359).